Cart
sales@molnova.com
(S)-Enitociclib
CAS No. 1610408-97-3
(S)-Enitociclib( —— )
Catalog No. M36340 CAS No. 1610408-97-3
(S)-Enitociclib (VIP152) is a selective CDK9 inhibitor that induces complete regression of MYC+ lymphomas by inhibiting RNA polymerase II-mediated transcription of anti-apoptotic and pro-survival proteins.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 715 | In Stock |
|
| 5MG | 1112 | In Stock |
|
| 10MG | 1359 | In Stock |
|
| 25MG | 1824 | In Stock |
|
| 50MG | 2213 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Name(S)-Enitociclib
-
NoteResearch use only, not for human use.
-
Brief Description(S)-Enitociclib (VIP152) is a selective CDK9 inhibitor that induces complete regression of MYC+ lymphomas by inhibiting RNA polymerase II-mediated transcription of anti-apoptotic and pro-survival proteins.
-
Description(S)-Enitociclib (VIP152) is a selective CDK9 inhibitor that induces complete regression of MYC+ lymphomas by inhibiting RNA polymerase II-mediated transcription of anti-apoptotic and pro-survival proteins.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetCDK
-
RecptorCDK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1610408-97-3
-
Formula Weight404.43
-
Molecular FormulaC19H18F2N4O2S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCOC1=C(C2=C(F)C=NC(NC3=CC(C[S@@](C)(=N)=O)=CC=N3)=C2)C=CC(F)=C1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
P18IN003
P18IN003 is a selective and effective p18(INK4C) inhibitor that inhibits the activity of p18 protein and can be used to study in vitro expansion of hematopoietic stem cells.
-
AS-0141
AS-0141 (Cdc7-IN-6) is a potent Cdc7 kinase inhibitor (IC50=4 nM) with anti-tumor activity.
-
Voruciclib
A potent, selective and orally bioavailable CDK9 inhibitor with Ki of 0.63 nM and 1.68 nM for CDK9/cyclinT2 and CDK9/cyclinT1.
